1.34 0.085 (6.77%) | 04-26 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 3.93 | 1-year : | 5.46 |
Resists | First : | 3.36 | Second : | 4.67 |
Pivot price | 1.86 | |||
Supports | First : | 1.25 | Second : | 1.04 |
MAs | MA(5) : | 1.39 | MA(20) : | 2.15 |
MA(100) : | 1.69 | MA(250) : | 3.12 | |
MACD | MACD : | -0.5 | Signal : | -0.4 |
%K %D | K(14,3) : | 3.1 | D(3) : | 3.4 |
RSI | RSI(14): 28.8 | |||
52-week | High : | 12.07 | Low : | 0.51 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ OCEA ] has closed above bottom band by 18.4%. Bollinger Bands are 6.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 1.43 - 1.44 | 1.44 - 1.45 |
Low: | 1.24 - 1.25 | 1.25 - 1.26 |
Close: | 1.32 - 1.34 | 1.34 - 1.36 |
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.
Wed, 24 Apr 2024
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K - GlobeNewswire
Mon, 18 Mar 2024
Ocean Biomedical: Shooting Upward, But Not Somewhere I Want To Be (Rating Upgrade) (OCEA) - Seeking Alpha
Fri, 08 Mar 2024
Ocean Biomedical Inc expected to post a loss of 15 cents a share - Earnings Preview - XM
Thu, 07 Mar 2024
Ocean Biomedical Inc options imply 31.8% move in share price post-earnings - TipRanks.com - TipRanks
Mon, 04 Mar 2024
OCEA Stock Quote Price and Forecast - CNN
Mon, 04 Mar 2024
Healthcare Stocks on the Move Monday: OCEA, LVTX, AIMD, RNLX, BIVI, FWBI, VANI, CDIO - InvestorsObserver
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 35 (M) |
Shares Float | 4 (M) |
Held by Insiders | 71.9 (%) |
Held by Institutions | 13.5 (%) |
Shares Short | 936 (K) |
Shares Short P.Month | 2,960 (K) |
EPS | -3 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -2.22 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -682 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -9 (M) |
Levered Free Cash Flow | 2 (M) |
PE Ratio | -0.45 |
PEG Ratio | 0 |
Price to Book value | -0.61 |
Price to Sales | 0 |
Price to Cash Flow | -5.4 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |